{"id":"sg001","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL5315040","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SG001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"SG001 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:11.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT07183865","phase":"PHASE2","title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-09","conditions":"Locally Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT06989671","phase":"PHASE2","title":"SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-08-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06682611","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-11-13","conditions":"Unresectable Locally Advanced or Metastatic Solid Tumors","enrollment":380},{"nctId":"NCT06645197","phase":"EARLY_PHASE1","title":"An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-10-16","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":7},{"nctId":"NCT05009953","phase":"PHASE2","title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","status":"TERMINATED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma","enrollment":17},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT06132217","phase":"PHASE1, PHASE2","title":"A Study of Simmitinib Plus SG001 in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-01-30","conditions":"Advanced Solid Tumor","enrollment":168},{"nctId":"NCT06089330","phase":"PHASE2","title":"A Study of JMT101 in Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":102},{"nctId":"NCT05715840","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-01-31","conditions":"Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)","enrollment":368},{"nctId":"NCT05508659","phase":"PHASE1, PHASE2","title":"A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2022-09-20","conditions":"Advanced Solid Tumors","enrollment":128},{"nctId":"NCT04886700","phase":"PHASE2","title":"Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-07-31","conditions":"Uterine Cervical Cancer","enrollment":104},{"nctId":"NCT05068141","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-10-01","conditions":"Triple Negative Breast Cancer","enrollment":79},{"nctId":"NCT04983550","phase":"PHASE2","title":"Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-09","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":126},{"nctId":"NCT03852823","phase":"PHASE1","title":"Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-05-23","conditions":"Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection","Recombinant Human Anti-PD-1 Monoclonal Antibody"],"phase":"phase_3","status":"active","brandName":"SG001","genericName":"SG001","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SG001 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}